Sponsors (4)
The bill strengthens biosafety, standardization, and intersector coordination for nucleic acid screening—improving public-health protection and research interoperability—while imposing modest federal costs and added compliance/oversight burdens on small labs and developers.
Hospitals, public-health agencies, and state governments will have stronger DNA/RNA synthesis screening, procurement access controls, and operational security, reducing the risk that harmful or unauthorized genetic sequences enter the supply chain.
Scientists, researchers, and biotech small businesses will gain standardized measurement tools and best practices for nucleic acid screening that improve assay accuracy, interoperability, and reduce time/costs for validation and collaboration.
Industry, academia, nonprofits, and government stakeholders get a formal venue to coordinate, build consensus, and develop roadmaps for biosafety standards, improving policy alignment and reducing fragmentation across sectors.
Small biotech firms, private labs, and individual researchers may face added compliance and implementation costs to adopt consensus standards and conformity assessments.
Including AI risk-management language could subject AI tools used in bioengineering to additional oversight, increasing compliance burdens and potentially slowing deployment and innovation by researchers and small companies.
Federal taxpayers will fund an estimated $5 million per year for the program, which could divert funding from other NIST programs or federal priorities.
Based on analysis of 2 sections of legislative text.
Authorizes NIST-led measurement research and a stakeholder consortium to develop technical standards, testing, and best practices for nucleic acid synthesis screening, with $5M/year authorized for FY2026–2030.
Introduced April 28, 2025 by Andrea Salinas · Last progress April 28, 2025
Directs NIST to lead measurement research and convene a stakeholder consortium to develop and improve technical standards, best practices, testing, and evaluation methods for nucleic acid synthesis screening, including consideration of AI-related risks. Authorizes $5,000,000 per year from NIST laboratory activities for each of fiscal years 2026–2030 and requires a report to congressional committees within 18 months of the consortium’s first meeting.